KT-253 by Kymera Therapeutics for Myeloproliferative Disorders: Likelihood of Approval

KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myeloproliferative Disorders.

Source link
#KT253 #Kymera #Therapeutics #Myeloproliferative #Disorders #Likelihood #Approval